Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionProduct descriptionProduct information

Dosage forms and strengths

2 evidence topics · 2 sources

Investigational product form and route in the pivotal trial
Registry fieldQuoted record
Pharmaceutical form“VIAL FOR INTRAVENOUS USE”
Route“SOLUTION FOR INFUSION”
Active substance origin“Protein - Other”
Vial strength and commercial formulation

No evidence found.